Table 3.
Treatment-emergent adverse event-associated resource use in RELAY
| Resource use | RAM + ERL (n = 221) |
PBO + ERL (n = 225) |
|---|---|---|
| Hospitalizations | ||
| Patients hospitalized due to AEs | 66 (29.9) | 44 (19.6) |
| Duration of hospitalization, days | 12 (1–67) | 11 (2–36) |
| Transfusions | ||
| Any transfusion | 8 (3.6) | 0 |
| Packed red blood cells | 7 (3.2) | 0 |
| Platelets | 2 (0.9) | 0 |
| Supportive care | ||
| Dermatological products | 195 (88.2) | 202 (89.8) |
| Topical steroids | 176 (79.6) | 187 (83.1) |
| Emollients and protectives | 133 (60.2) | 128 (56.9) |
| Antibiotics | 92 (41.6) | 77 (34.2) |
| Systemic antimicrobials | 194 (87.8) | 192 (85.3) |
| Antibiotics | 191 (86.4) | 190 (84.4) |
| Antivirals | 19 (8.6) | 19 (8.4) |
| Antifungals | 7 (3.2) | 4 (1.8) |
| Analgesics | 173 (78.3) | 147 (65.3) |
| Antihypertensives | 153 (69.2) | 95 (42.2) |
| Calcium channel antagonists | 110 (49.8) | 56 (24.9) |
| Angiotensin II inhibitors | 108 (48.9) | 60 (26.7) |
| Diuretics | 49 (22.2) | 16 (7.1) |
| H1 antagonists | 135 (61.1) | 123 (54.7) |
| Antidiarrheals | 130 (58.8) | 126 (56.0) |
| Acid suppressants/protectants | 116 (52.5) | 109 (48.4) |
| Stomatological preparations | 103 (46.6) | 82 (36.4) |
| Systemic corticosteroids | 77 (34.8) | 84 (37.3) |
| Antiemetics | 76 (34.4) | 63 (28.0) |
| Antihemorrhagics | 30 (13.6) | 13 (5.8) |
| Bone modifiers | 29 (13.1) | 25 (11.1) |
| Anticoagulants | 19 (8.6) | 12 (5.3) |
| Antiplatelets | 17 (7.7) | 16 (7.1) |
| Appetite stimulants | 13 (5.9) | 12 (5.3) |
| Granulocyte colony-stimulating factors | 2 (0.9) | 1 (0.4) |
Data are presented as n (%) or median (range)
AE treatment-emergent adverse event, ERL erlotinib, H1 histamine receptor 1, PBO placebo, RAM ramucirumab